Phospholipid Scramblase 4 (PLSCR4) Regulates Adipocyte Differentiation via PIP3-Mediated AKT Activation.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
29 Aug 2022
Historique:
received: 07 07 2022
revised: 18 08 2022
accepted: 24 08 2022
entrez: 9 9 2022
pubmed: 10 9 2022
medline: 14 9 2022
Statut: epublish

Résumé

Phospholipid scramblase 4 (PLSCR4) is a member of a conserved enzyme family with high relevance for the remodeling of phospholipid distribution in the plasma membrane and the regulation of cellular signaling. While PLSCR1 and -3 are involved in the regulation of adipose-tissue expansion, the role of PLSCR4 is so far unknown. PLSCR4 is significantly downregulated in an adipose-progenitor-cell model of deficiency for phosphatase and tensin homolog (PTEN). PTEN acts as a tumor suppressor and antagonist of the growth and survival signaling phosphoinositide 3-kinase (PI3K)/AKT cascade by dephosphorylating phosphatidylinositol-3,4,5-trisphosphate (PIP3). Patients with PTEN germline deletion frequently develop lipomas. The underlying mechanism for this aberrant adipose-tissue growth is incompletely understood. PLSCR4 is most highly expressed in human adipose tissue, compared with other phospholipid scramblases, suggesting a specific role of PLSCR4 in adipose-tissue biology. In cell and mouse models of lipid accumulation, we found PLSCR4 to be downregulated. We observed increased adipogenesis in PLSCR4-knockdown adipose progenitor cells, while PLSCR4 overexpression attenuated lipid accumulation. PLSCR4 knockdown was associated with increased PIP3 levels and the activation of AKT. Our results indicated that PLSCR4 is a regulator of PI3K/AKT signaling and adipogenesis and may play a role in PTEN-associated adipose-tissue overgrowth and lipoma formation.

Identifiants

pubmed: 36077184
pii: ijms23179787
doi: 10.3390/ijms23179787
pmc: PMC9456373
pii:
doi:

Substances chimiques

PLSCR4 protein, human 0
Phosphatidylinositols 0
Phospholipid Transfer Proteins 0
Proto-Oncogene Proteins c-akt EC 2.7.11.1
PTEN Phosphohydrolase EC 3.1.3.67

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Deutsche Forschungsgemeinschaft
ID : SFB 1052-209933838, Project numbers B10 (A.G., D.L.D., L.A.G.B., A.S.K., A.V., W.K., M N.), Z3 (P.P.), Z4 (S.K.) and Z2 (open access publishing)

Références

Eur J Med Genet. 2021 Dec;64(12):104364
pubmed: 34637944
BMC Genomics. 2021 Nov 7;22(1):802
pubmed: 34743696
Biochemistry. 2004 Mar 30;43(12):3518-26
pubmed: 15035622
Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13296-301
pubmed: 15328404
Bioinformatics. 2010 Sep 15;26(18):2334-5
pubmed: 20624783
Ann Transl Med. 2021 Jan;9(2):159
pubmed: 33569461
Nat Genet. 2013 Jun;45(6):580-5
pubmed: 23715323
Pediatr Res. 2014 Apr;75(4):527-34
pubmed: 24366516
Int J Obes (Lond). 2021 Mar;45(3):565-576
pubmed: 33235355
Sci Rep. 2021 Nov 12;11(1):22199
pubmed: 34772994
Front Endocrinol (Lausanne). 2020 Mar 26;11:138
pubmed: 32273869
Nucleic Acids Res. 2004 Mar 19;32(5):1792-7
pubmed: 15034147
Biochemistry. 2002 May 21;41(20):6338-45
pubmed: 12009895
Biochim Biophys Acta. 2000 Jul 31;1467(1):244-53
pubmed: 10930526
Front Psychiatry. 2013 Nov 28;4:154
pubmed: 24348429
Methods Mol Biol. 2020;2127:207-225
pubmed: 32112325
Cytogenet Genome Res. 2012;137(2-4):113-29
pubmed: 22777195
PLoS One. 2015 Aug 28;10(8):e0136729
pubmed: 26317218
J Clin Invest. 2021 Jan 4;131(1):
pubmed: 33393497
Adipocyte. 2020 Dec;9(1):290-301
pubmed: 32579864
FEBS Lett. 2015 Jan 2;589(1):3-14
pubmed: 25479087
Nat Methods. 2011 Mar;8(3):267-72
pubmed: 21278744
Cancers (Basel). 2019 Jun 18;11(6):
pubmed: 31216739
J Biol Chem. 2021 Aug;297(2):100968
pubmed: 34273354
Nucleic Acids Res. 2014 Jan;42(Database issue):D917-21
pubmed: 24225318
Genes Dev. 2005 Sep 15;19(18):2138-51
pubmed: 16166378
Nat Methods. 2012 Jul;9(7):671-5
pubmed: 22930834
J Sci Food Agric. 2012 Jan 30;92(2):388-96
pubmed: 21918993

Auteurs

Lisa A G Barth (LAG)

University Hospital for Children & Adolescents, Center for Pediatric Research, Leipzig University, 04103 Leipzig, Germany.

Michèle Nebe (M)

University Hospital for Children & Adolescents, Center for Pediatric Research, Leipzig University, 04103 Leipzig, Germany.

Hermann Kalwa (H)

Institute of Pharmacology, Pharmacy and Toxicology, Leipzig University, 04107 Leipzig, Germany.

Akhil Velluva (A)

Institute of Human Genetics, Leipzig University Medical Center, 04103 Leipzig, Germany.
Department of Evolutionary Genetics, Max Planck Institute for Evolutionary Anthropology, 04103 Leipzig, Germany.

Stephanie Kehr (S)

Bioinformatics Group, Department of Computer Science and Interdisciplinary Center for Bioinformatics, Leipzig University, 04107 Leipzig, Germany.

Florentien Kolbig (F)

University Hospital for Children & Adolescents, Center for Pediatric Research, Leipzig University, 04103 Leipzig, Germany.

Patricia Prabutzki (P)

Institute for Medical Physics and Biophysics, Leipzig University, 04107 Leipzig, Germany.

Wieland Kiess (W)

University Hospital for Children & Adolescents, Center for Pediatric Research, Leipzig University, 04103 Leipzig, Germany.

Diana Le Duc (D)

Institute of Human Genetics, Leipzig University Medical Center, 04103 Leipzig, Germany.
Department of Evolutionary Genetics, Max Planck Institute for Evolutionary Anthropology, 04103 Leipzig, Germany.

Antje Garten (A)

University Hospital for Children & Adolescents, Center for Pediatric Research, Leipzig University, 04103 Leipzig, Germany.

Anna S Kirstein (AS)

University Hospital for Children & Adolescents, Center for Pediatric Research, Leipzig University, 04103 Leipzig, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH